[HTML][HTML] Statins, muscle disease and mitochondria
R Ramachandran, AS Wierzbicki - Journal of clinical medicine, 2017 - mdpi.com
Cardiovascular disease (CVD) accounts for> 17 million deaths globally every year, and this
figure is predicted to rise to> 23 million by 2030. Numerous studies have explored the …
figure is predicted to rise to> 23 million by 2030. Numerous studies have explored the …
Statin-associated rhabdomyolysis: is there a dose-response relationship?
A Holbrook, M Wright, M Sung, C Ribic… - Canadian Journal of …, 2011 - Elsevier
Background Statins have a well-established role in prevention of vascular events but are
associated with muscle-related adverse events. The dose relationship with these adverse …
associated with muscle-related adverse events. The dose relationship with these adverse …
Cerivastatin nanoliposome as a potential disease modifying approach for the treatment of pulmonary arterial hypertension
Y Lee, SB Pai, RV Bellamkonda, DH Thompson… - … of Pharmacology and …, 2018 - ASPET
In this study we investigated nanoliposome as an approach to tailoring the pharmacology of
cerivastatin as a disease-modifying drug for pulmonary arterial hypertension (PAH) …
cerivastatin as a disease-modifying drug for pulmonary arterial hypertension (PAH) …
[HTML][HTML] Dihydroaustrasulfone alcohol (WA-25) impedes macrophage foam cell formation by regulating the transforming growth factor-β1 pathway
YC Wang, HC Hung, CW Feng, SY Huang… - International journal of …, 2015 - mdpi.com
Atherosclerosis is considered an inflammatory disease. However, clinically used anti-
atherosclerotic drugs, such as simvastatin, have many side effects. Recently, several unique …
atherosclerotic drugs, such as simvastatin, have many side effects. Recently, several unique …
Chemoenzymatic Synthesis of Chiral Alcohols Relevant to Pharmaceutical Industry
NYC Thai - tuprints.ulb.tu-darmstadt.de
1. From 1987 on, statins have been introduced to the market as cholesterol lowering agents
and have, ever since, settled their position as one of the most prescribed drugs for the …
and have, ever since, settled their position as one of the most prescribed drugs for the …
[PDF][PDF] インデックスリンク
山浦優 - kanazawa-u.repo.nii.ac.jp
第 2 節 実験材料および実験方法 7 II-2-1 実験材料および試薬 7 II-2-2 肝障害患者の血清 7 II-2-3
mirVana PARIS Kit を用いた血漿からの RNA の抽出 9 II-2-4 RT 反応による cDNA の合成 9 II-2 …
mirVana PARIS Kit を用いた血漿からの RNA の抽出 9 II-2-4 RT 反応による cDNA の合成 9 II-2 …
Trends in the use of statins in Lithuania on 2005–2007 years
I Paulauskaitė - 2008 - lsmu.lt
Objective: To compare statins according to the pharmacokinetic and pharmacodynamic
characteristics within the drug class and to perform the comprehensive analysis of statins …
characteristics within the drug class and to perform the comprehensive analysis of statins …
[PDF][PDF] 血清中 microRNA を用いた臨床及び非臨床における新規バイオマーカーの確立に向けた研究
山浦優 - 2020 - kanazawa-u.repo.nii.ac.jp
第 2 節 実験材料および実験方法 7 II-2-1 実験材料および試薬 7 II-2-2 肝障害患者の血清 7 II-2-3
mirVana PARIS Kit を用いた血漿からの RNA の抽出 9 II-2-4 RT 反応による cDNA の合成 9 II-2 …
mirVana PARIS Kit を用いた血漿からの RNA の抽出 9 II-2-4 RT 反応による cDNA の合成 9 II-2 …
Estudio Descriptivo de las Reacciones Adversas y las Características Farmacológicas de la Cerivastatina: Una Revisión de la Farmacovigilancia Continua
LÁF Sorroza López - 2015 - repositorio.lasalle.mx
La cerivastatina es un compuesto sintético del grupo de las estatinas, fármacos inhibidores
competitivos de la enzima HMG-CoA reductasa, es sujeto de un doble metabolismo …
competitivos de la enzima HMG-CoA reductasa, es sujeto de un doble metabolismo …
[CITATION][C] Rhabdomyolysis
NS Sroufe, RM Stanley - Pediatric Emergency Medicine, 2007 - ohiostate.elsevierpure.com
Rhabdomyolysis — The Ohio State University Skip to main navigation Skip to search Skip to
main content The Ohio State University Home The Ohio State University Logo Home …
main content The Ohio State University Home The Ohio State University Logo Home …